KROS
Keros Therapeutics Inc
NASDAQ · Biotechnology
$17.57
+0.33 (+1.91%)
Open$17.45
Previous Close$17.24
Day High$17.90
Day Low$17.35
52W High$22.55
52W Low$9.12
Volume—
Avg Volume258.3K
Market Cap535.29M
P/E Ratio8.31
EPS$1.54
SectorBiotechnology
Analyst Ratings
Buy
16 analysts
Price Target
+12.1% upside
Current
$17.57
$17.57
Target
$19.70
$19.70
$13.49
$19.70 avg
$20.36
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 2.89M | 5.15M | 97.48M |
| Net Income | -152,464,386 | -244,551,679 | -15,590,568 |
| Profit Margin | -5,277.6% | -5,013.7% | -16.0% |
| EBITDA | -170,341,874 | -288,406,309 | -19,293,481 |
| Free Cash Flow | — | — | -15,397,530 |
| Rev Growth | -43.9% | -43.9% | -0.3% |
| Debt/Equity | — | — | 0.56 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |